Advertisement

Drugs

, Volume 79, Issue 15, pp 1625–1634 | Cite as

Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs)

  • Megan C. HerinkEmail author
  • Yan F. Zhuo
  • Craig D. Williams
  • Thomas G. DeLoughery
Review Article

Abstract

Compared with warfarin, the direct-acting oral anticoagulants (DOAC) have fewer pharmacokinetic drug interactions. However, significant drug interactions do exist with documented changes in DOAC concentrations, which can exceed 100%. Unlike warfarin, DOACs have no validated surrogate test to monitor the intensity of anticoagulation. However, several analyses of major outcomes trials with DOACs have demonstrated that serum concentrations do affect both the thrombotic benefits and the hemorrhagic risks of these agents. This paper reviews the known significant pharmacokinetic interactions with DOACs and includes considerations for their use in the presence of interacting medications.

Notes

Compliance with Ethical Standards

Funding

No sources of funding were used to conduct this study or prepare this manuscript.

Conflict of interest

MH, YZ, CW and TD have no potential conflicts of interest that might be relevant to the contents of this manuscript.

References

  1. 1.
    Wiggins BS, Northup A, Johnson D, Senfield J. Reduced anticoagulant effect of dabigatran in a patient receiving concomitant phenytoin. Pharmacotherapy. 2016;36(2):e5–7.  https://doi.org/10.1002/phar.1698.CrossRefPubMedGoogle Scholar
  2. 2.
    Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29(7 Suppl):S24–33.  https://doi.org/10.1016/j.cjca.2013.04.002.CrossRefPubMedGoogle Scholar
  3. 3.
    Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI. Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review. JAMA Cardiol. 2017;2(5):566–74.  https://doi.org/10.1001/jamacardio.2017.0364.CrossRefPubMedGoogle Scholar
  4. 4.
    Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455–66.  https://doi.org/10.1111/bcp.12075.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hartter S, Koenen-Bergmann M, Sharma A, Nehmiz G, Lemke U, Timmer W, et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol. 2012;74(3):490–500.  https://doi.org/10.1111/j.1365-2125.2012.04218.x.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75(2):476–87.  https://doi.org/10.1111/j.1365-2125.2012.04369.x.CrossRefPubMedGoogle Scholar
  7. 7.
    Liesenfeld KH, Schafer HG, Troconiz IF, Tillmann C, Eriksson BI, Stangier J. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol. 2006;62(5):527–37.  https://doi.org/10.1111/j.1365-2125.2006.02667.x.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, et al. Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2288–95.  https://doi.org/10.1016/S0140-6736(14)61943-7.CrossRefPubMedGoogle Scholar
  9. 9.
    Testa S, Paoletti O, Legnani C, Dellanoce C, Antonucci E, Cosmi B, et al. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost. 2018;16(5):842–8.  https://doi.org/10.1111/jth.14001.CrossRefPubMedGoogle Scholar
  10. 10.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.  https://doi.org/10.1056/NEJMoa0905561.CrossRefPubMedGoogle Scholar
  11. 11.
    Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321–8.  https://doi.org/10.1016/j.jacc.2013.07.104.CrossRefPubMedGoogle Scholar
  12. 12.
    Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17.  https://doi.org/10.1056/NEJMoa1007432.CrossRefPubMedGoogle Scholar
  13. 13.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.  https://doi.org/10.1056/NEJMoa1009638.CrossRefPubMedGoogle Scholar
  14. 14.
    Investigators E-P, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97.  https://doi.org/10.1056/NEJMoa1113572.CrossRefGoogle Scholar
  15. 15.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.  https://doi.org/10.1056/NEJMoa1107039.CrossRefPubMedGoogle Scholar
  16. 16.
    Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013;34(27):2094–106.  https://doi.org/10.1093/eurheartj/eht134.CrossRefPubMedGoogle Scholar
  17. 17.
    Evans WE, McLeod HL. Pharmacogenomics–drug disposition, drug targets, and side effects. N Engl J Med. 2003;348(6):538–49.  https://doi.org/10.1056/NEJMra020526.CrossRefPubMedGoogle Scholar
  18. 18.
    Sanford M, Plosker GL. Dabigatran etexilate. Drugs. 2008;68(12):1699–709.CrossRefGoogle Scholar
  19. 19.
    Lind SE, Callas PW, Golden EA, Joyner KA Jr, Ortel TL. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis. 1997;8(1):48–53.CrossRefGoogle Scholar
  20. 20.
    Administration FaD. Clinical Drug Interaction Studies - Study Design, Data Analysis, and Clinical Implications. In: Research CfDEa, editor; 2017.Google Scholar
  21. 21.
    Gordon LA, Kumar P, Brooks KM, Kellogg A, McManus M, Alfaro RM, et al. Antiretroviral boosting agent cobicistat increases the pharmacokinetic exposure and anticoagulant effect of dabigatran in HIV-negative healthy volunteers. Circulation. 2016;134(23):1909–11.  https://doi.org/10.1161/CIRCULATIONAHA.116.025257.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Delavenne X, Ollier E, Basset T, Bertoletti L, Accassat S, Garcin A, et al. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol. 2013;76(1):107–13.  https://doi.org/10.1111/bcp.12055.CrossRefPubMedGoogle Scholar
  23. 23.
    Hartter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa((R))) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75(4):1053–62.  https://doi.org/10.1111/j.1365-2125.2012.04453.x.CrossRefPubMedGoogle Scholar
  24. 24.
    Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168–75.  https://doi.org/10.1111/j.1538-7836.2011.04498.x.CrossRefPubMedGoogle Scholar
  25. 25.
    Pradaxa [Package Insert]. Boehringer Ingelheim Pharmaceuticals Inc; 2015.Google Scholar
  26. 26.
    Hsyu PH, Pignataro DS, Matschke K. Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. Eur J Clin Pharmacol. 2017;73(1):57–63.  https://doi.org/10.1007/s00228-016-2115-0.CrossRefPubMedGoogle Scholar
  27. 27.
    Stangier J, Stahle H, Rathgen K, Roth W, Reseski K, Kornicke T. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. J Clin Pharmacol. 2012;52(2):243–50.  https://doi.org/10.1177/0091270010393342.CrossRefPubMedGoogle Scholar
  28. 28.
    Stangier J, Rathgen K, Stahle H, Reseski K, Kornicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs. 2009;9(1):59–68.  https://doi.org/10.2165/00129784-200909010-00006.CrossRefPubMedGoogle Scholar
  29. 29.
    Hartter S, Sennewald R, Schepers C, Baumann S, Fritsch H, Friedman J. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Eur J Clin Pharmacol. 2013;69(3):327–39.  https://doi.org/10.1007/s00228-012-1304-8.CrossRefPubMedGoogle Scholar
  30. 30.
    Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47–59.  https://doi.org/10.2165/00003088-200847010-00005.CrossRefPubMedGoogle Scholar
  31. 31.
    Parasrampuria DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016;82(6):1591–600.  https://doi.org/10.1111/bcp.13092.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Mendell J, Chen S, He L, Desai M, Parasramupria DA. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. Clin Drug Investig. 2015;35(7):447–53.  https://doi.org/10.1007/s40261-015-0298-2.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharmacol Drug Dev. 2013;2(4):358–66.  https://doi.org/10.1002/cpdd.53.CrossRefPubMedGoogle Scholar
  34. 34.
    Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M. In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Pharmacol Ther. 2000;68(4):401–11.  https://doi.org/10.1067/mcp.2000.110561.CrossRefPubMedGoogle Scholar
  35. 35.
    Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13(5):331–42.  https://doi.org/10.1007/s40256-013-0029-0.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Mendell J, Lee F, Chen S, Worland V, Shi M, Samama MM. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. J Cardiovasc Pharmacol. 2013;62(2):212–21.  https://doi.org/10.1097/FJC.0b013e3182970991.CrossRefPubMedGoogle Scholar
  37. 37.
    Frost CE, Byon W, Song Y, Wang J, Schuster AE, Boyd RA, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol. 2015;79(5):838–46.  https://doi.org/10.1111/bcp.12541.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Vakkalagadda B, Frost C, Byon W, Boyd RA, Wang J, Zhang D, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. Am J Cardiovasc Drugs. 2016;16(2):119–27.  https://doi.org/10.1007/s40256-015-0157-9.CrossRefPubMedGoogle Scholar
  39. 39.
    Frost C, Shenker A, Gandhi MD, Pursley J, Barrett YC, Wang J, et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol. 2014;78(4):877–85.  https://doi.org/10.1111/bcp.12393.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Zrieki A, Farinotti R, Buyse M. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm Res. 2008;25(9):1991–2001.  https://doi.org/10.1007/s11095-008-9596-1.CrossRefPubMedGoogle Scholar
  41. 41.
    Zhang D, He K, Herbst JJ, Kolb J, Shou W, Wang L, et al. Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013;41(4):827–35.  https://doi.org/10.1124/dmd.112.050260.CrossRefPubMedGoogle Scholar
  42. 42.
    Garonzik S, Byon W, Myers E, Li X, Marchisin D, Murthy B. The effects of clarithromycin on the pharmacokinetics of apixaban in healthy volunteers: a single-sequence crossover study. Am J Cardiovasc Drugs. 2019.  https://doi.org/10.1007/s40256-019-00348-2.CrossRefPubMedGoogle Scholar
  43. 43.
    Upreti VV, Song Y, Wang J, Byon W, Boyd RA, Pursley JM, et al. Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Clin Pharmacol. 2013;5:59–66.  https://doi.org/10.2147/CPAA.S41999.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Frost C, Song Y, Yu Z, Wang J, Lee LS, Schuster A, et al. The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects. Clin Pharmacol. 2017;9:19–28.  https://doi.org/10.2147/CPAA.S115687.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Moore KT, Vaidyanathan S, Natarajan J, Ariyawansa J, Haskell L, Turner KC. An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function. J Clin Pharmacol. 2014;54(12):1407–20.  https://doi.org/10.1002/jcph.352.CrossRefPubMedGoogle Scholar
  46. 46.
    Administration FaD. rivaroxaban package insert; 2019.Google Scholar
  47. 47.
    Kubitza D, Becka M, Roth A, Mueck W. Absence of clinically relevant interactions between rivaroxaban—an oral, direct factor Xa inhibitor—and digoxin or atorvastatin in healthy subjects. J Int Med Res. 2012;40(5):1688–707.  https://doi.org/10.1177/030006051204000508.CrossRefPubMedGoogle Scholar
  48. 48.
    Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939)—an oral, direct factor Xa inhibitor—has no clinically relevant interaction with naproxen. Br J Clin Pharmacol. 2007;63(4):469–76.  https://doi.org/10.1111/j.1365-2125.2006.02776.x.CrossRefPubMedGoogle Scholar
  49. 49.
    Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct factor Xa inhibitor—are not affected by aspirin. J Clin Pharmacol. 2006;46(9):981–90.  https://doi.org/10.1177/0091270006292127.CrossRefPubMedGoogle Scholar
  50. 50.
    Moore KT, Plotnikov AN, Thyssen A, Vaccaro N, Ariyawansa J, Burton PB. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. J Cardiovasc Pharmacol. 2011;58(6):581–8.  https://doi.org/10.1097/FJC.0b013e31822f6c2b.CrossRefPubMedGoogle Scholar
  51. 51.
    Hokusai VTEI, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–15.  https://doi.org/10.1056/NEJMoa1306638.CrossRefGoogle Scholar
  52. 52.
    Hirsh Raccah B, Rottenstreich A, Zacks N, Muszkat M, Matok I, Perlman A, et al. Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients. J Thromb Thrombolysis. 2018;46(4):521–7.  https://doi.org/10.1007/s11239-018-1738-7.CrossRefPubMedGoogle Scholar
  53. 53.
    Sakaguchi T, Osanai H, Murase Y, Ishii H, Nakashima Y, Asano H, et al. Monitoring of anti-Xa activity and factors related to bleeding events: a study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban. J Cardiol. 2017;70(3):244–9.  https://doi.org/10.1016/j.jjcc.2016.11.013.CrossRefPubMedGoogle Scholar
  54. 54.
    Chang SH, Chou IJ, Yeh YH, Chiou MJ, Wen MS, Kuo CT, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA. 2017;318(13):1250–9.  https://doi.org/10.1001/jama.2017.13883.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Administration FaD. Clinical Pharmacology and Biopharmaceutics Review: Xarelto. http://www.fda.gov2010.
  56. 56.
    Administration FaD. Clinical pharmacology and biopharmaceutics review: Eliquis. In: Research CfEa, editor. http://www.fda.gov2012.
  57. 57.
    Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257–354.  https://doi.org/10.1161/CIRCULATIONAHA.106.177292.CrossRefPubMedGoogle Scholar
  58. 58.
    Perlman A, Hochberg-Klein S, Choshen Cohen L, Dagan G, Hirsh-Raccah B, Horwitz E, et al. Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. J Thromb Thrombolysis. 2019;47(4):590–5.  https://doi.org/10.1007/s11239-018-01804-7.CrossRefPubMedGoogle Scholar
  59. 59.
    Di Gennaro L, Lancellotti S, De Cristofaro R, De Candia E. Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy. J Thromb Thrombolysis. 2019.  https://doi.org/10.1007/s11239-019-01866-1.CrossRefPubMedGoogle Scholar
  60. 60.
    Administration FaD. Clinical Pharamcology and Biopharmaceutics Review: Pradaxa. In: Research CfDEa, editor; 2010.Google Scholar
  61. 61.
    Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46(5):549–58.  https://doi.org/10.1177/0091270006286904.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Pharmacy PracticeOSU/OHSU College of PharmacyPortlandUSA
  2. 2.Department of HematologyOHSU School of MedicinePortlandUSA

Personalised recommendations